Breaking News Instant updates and real-time market news.

PFE

Pfizer

$36.63

0.1 (0.27%)

07:35
04/23/18
04/23
07:35
04/23/18
07:35

Pfizer announces European Commission approval of Mylotarg combination

Pfizer announced that the European Commission has approved Mylotarg in combination with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo, CD33-positive acute myeloid leukemia, or AML, except acute promyelocytic leukemia. Mylotarg is the first and only AML therapy approved in the European Union, or EU, that targets CD33, an antigen expressed on AML cells in up to 90% of patients. The goal of AML treatment is for the patient to achieve a complete, prolonged remission. Longer periods of remission prior to relapse are associated with better long-term outcomes for patients. Thus, medicines that delay the time until the disease comes back and extend life can provide meaningful clinical benefit. The European Commission's approval of Mylotarg was based on data from an investigator-led, Phase 3 randomized, open-label study in previously untreated, de novo patients. Mylotarg received approval by the FDA in September 2017 for adults with newly diagnosed CD33-positive acute myeloid leukemia, and adults and children 2 years and older with relapsed or refractory CD33-positive AML.

  • 24

    Apr

  • 25

    Apr

  • 08

    May

  • 05

    Jun

PFE Pfizer
$36.63

0.1 (0.27%)

04/12/18
SBSH
04/12/18
NO CHANGE
SBSH
Sell
Pfizer has no interest in acquiring Bristol-Myers right now, says Citi
Citi analyst Andrew Baum says Pfizer's (PFE) CEO made it clear to him that the company has no interest in acquiring Bristol-Myers Squibb (BMY) in the absence of transformational data or a de-rating in the shares. Pfizer has high conviction in its current pipeline and believes that the return on investment is considerably higher than high risk transformational deals, particularly in the immuno-oncology space, Baum tells investors in a research note. The analyst expects Pfizer will meaningfully increase its current share repurchase program from the current $5B-$6B per annum to offset the earnings dilution from higher anticipated R&D investment to monetize its current pipeline. Baum keeps a Sell rating on Pfizer and continues to prefer shares of Merck (MRK), Bristol and Eli Lilly (LLY) in the U.S. The analyst lowered his price target for Bristol shares to $70 from $78 with Pfizer backing away from a potential takeover. He keeps a Buy rating on the shares, however.
04/12/18
SBSH
04/12/18
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $78 at Citi
Citi analyst Andrew Baum lowered his price target for Bristol-Myers Squibb (BMY) to $70 after Pfizer (PFE) management made clear to him that they had no interest in acquiring Bristol without transformational data or a de-rating in the shares. The analyst removed the $8 per share risk adjusted M&A premium from his Bristol-Myers target price. He views his new price target as conservative, however, and keeps a Buy rating on the name.
04/16/18
NORL
04/16/18
NO CHANGE
NORL
Outperform
Pfizer appears to be BioLife Solutions customer, says Northland
Northland analyst Suraj Kalia believes Pfizer (PFE) has never publicly announced itself as a customer of BioLife Solutions (BLFS), but a link to a presentation apparently made at the AAPS conference seems to highlight Pfizer' use of BioLife's CryoStor cryopreservation medium in its CAR-T program. Kalie noted this is the first time he has learned of Pfizer being a customer and of the use of BioLife's CryoStor being used in allogeneic CAR-T applications, both of which he finds interesting. Kalia has an Outperform rating on BioLife.
04/19/18
04/19/18
NO CHANGE

BTIG says Allergan may be interested in Shire after insufficient Takeda offers
BTIG analyst Timothy Chiang noted that Shire (SHPG) is trading higher after news that at least one other company other than Takeda (TKPYY) is interested in acquiring Shire, and naming Allergan (AGN) as one of those possible suitors. Chiang also believes that other companies, such as Pfizer (PFE), could entering into the bidding for Shire. BTIG maintained a Buy rating and $195 price target on Shire shares.

TODAY'S FREE FLY STORIES

NTAP

NetApp

$66.61

-0.41 (-0.61%)

06:03
05/24/18
05/24
06:03
05/24/18
06:03
Recommendations
NetApp analyst commentary  »

NetApp target raised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

  • 12

    Jun

  • 10

    Jul

PEGI

Pattern Energy

$18.08

0.23 (1.29%)

06:03
05/24/18
05/24
06:03
05/24/18
06:03
Hot Stocks
Pattern Energy selling operations in Chile for $67M »

Pattern Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$15.10

-0.6 (-3.82%)

06:02
05/24/18
05/24
06:02
05/24/18
06:02
Downgrade
Petrobras rating change  »

Petrobras downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BWXT

BWX Technologies

$67.94

-0.06 (-0.09%)

06:02
05/24/18
05/24
06:02
05/24/18
06:02
Downgrade
BWX Technologies rating change  »

BWX Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$156.59

1.52 (0.98%)

05:49
05/24/18
05/24
05:49
05/24/18
05:49
Upgrade
Deere rating change  »

UBS upgrades Deere to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKTR

Nektar

$82.81

0.87 (1.06%)

, BMY

Bristol-Myers

$52.49

0.14 (0.27%)

05:36
05/24/18
05/24
05:36
05/24/18
05:36
Recommendations
Nektar, Bristol-Myers, Merck analyst commentary  »

Nektar is…

NKTR

Nektar

$82.81

0.87 (1.06%)

BMY

Bristol-Myers

$52.49

0.14 (0.27%)

MRK

Merck

$59.16

0.7 (1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 02

    Jun

  • 05

    Jun

  • 12

    Jun

  • 10

    Jul

  • 10

    Sep

  • 23

    Oct

ABBV

AbbVie

$105.60

-0.72 (-0.68%)

05:34
05/24/18
05/24
05:34
05/24/18
05:34
Downgrade
AbbVie rating change  »

AbbVie downgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 05

    Jun

GBNK

Guaranty Bancorp

$33.05

0.6 (1.85%)

, IBTX

Independent Bank

$74.20

-3.65 (-4.69%)

05:29
05/24/18
05/24
05:29
05/24/18
05:29
Downgrade
Guaranty Bancorp, Independent Bank rating change  »

Guaranty Bancorp…

GBNK

Guaranty Bancorp

$33.05

0.6 (1.85%)

IBTX

Independent Bank

$74.20

-3.65 (-4.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

EC

Ecopetrol

$21.15

-0.62 (-2.85%)

05:28
05/24/18
05/24
05:28
05/24/18
05:28
Upgrade
Ecopetrol rating change  »

Ecopetrol upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRML

Vermillion

$1.05

0.045 (4.48%)

05:27
05/24/18
05/24
05:27
05/24/18
05:27
Downgrade
Vermillion rating change  »

Vermillion downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.50

-0.15 (-1.19%)

05:26
05/24/18
05/24
05:26
05/24/18
05:26
Initiation
Caesars initiated  »

Caesars initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNT

Melinta Therapeutics

$6.25

-0.2 (-3.10%)

05:26
05/24/18
05/24
05:26
05/24/18
05:26
Syndicate
Melinta Therapeutics 22M share Secondary priced at $5.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

TDY

Teledyne

$198.96

2.19 (1.11%)

05:24
05/24/18
05/24
05:24
05/24/18
05:24
Hot Stocks
Teledyne awarded second phase of $47M contract from ESA »

The European Space…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOG

Northern Oil and Gas

$2.69

0.06 (2.28%)

05:22
05/24/18
05/24
05:22
05/24/18
05:22
Upgrade
Northern Oil and Gas rating change  »

Northern Oil and Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDC

Rowan Companies

05:22
05/24/18
05/24
05:22
05/24/18
05:22
Upgrade
Rowan Companies rating change  »

Rowan Companies upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OI

Owens-Illinois

$18.85

-0.1 (-0.53%)

05:21
05/24/18
05/24
05:21
05/24/18
05:21
Upgrade
Owens-Illinois rating change  »

Owens-Illinois upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$156.59

1.52 (0.98%)

05:21
05/24/18
05/24
05:21
05/24/18
05:21
Upgrade
Deere rating change  »

Deere upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNRC

Generac

$50.56

0.42 (0.84%)

05:21
05/24/18
05/24
05:21
05/24/18
05:21
Downgrade
Generac rating change  »

Generac downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

PBR

Petrobras

$15.10

-0.6 (-3.82%)

05:19
05/24/18
05/24
05:19
05/24/18
05:19
Downgrade
Petrobras rating change  »

Petrobras downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$15.10

-0.6 (-3.82%)

05:19
05/24/18
05/24
05:19
05/24/18
05:19
Downgrade
Petrobras rating change  »

Petrobras downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$76.38

-0.465 (-0.61%)

05:19
05/24/18
05/24
05:19
05/24/18
05:19
Hot Stocks
Sandoz receives European Commission approval for Zessly »

Sandoz, a Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

ARCT

Arcturus Therapeutics

$6.66

-0.29 (-4.17%)

05:17
05/24/18
05/24
05:17
05/24/18
05:17
Hot Stocks
Arcturus Therapeutics comments on court ruling on former CEO 13D situation »

Arcturus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

MTDR

Matador

$31.07

-0.735 (-2.31%)

05:14
05/24/18
05/24
05:14
05/24/18
05:14
Recommendations
Matador analyst commentary  »

Matador 'geared…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESYJY

easyJet

$0.00

(0.00%)

05:08
05/24/18
05/24
05:08
05/24/18
05:08
Downgrade
easyJet rating change  »

easyJet downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRMW

Primo Water

$15.48

0.56 (3.75%)

05:05
05/24/18
05/24
05:05
05/24/18
05:05
Initiation
Primo Water initiated  »

Primo Water initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.